Squadron Capital Llc Sells 10,131 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 10,131 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total value of $234,026.10. Following the sale, the insider owned 6,526,633 shares of the company’s stock, valued at $150,765,222.30. The trade was a 0.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Friday, August 28th, Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00.
• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.74, for a total transaction of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Trading Down 0.9%

KIDS opened at $22.80 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company’s 50 day simple moving average is $21.68 and its two-hundred day simple moving average is $18.80. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The firm has a market capitalization of $595.31 million, a price-to-earnings ratio of -13.57 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. Analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after buying an additional 1,235 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth about $34,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after acquiring an additional 2,561 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KIDS has been the subject of several research reports. BTIG Research boosted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Needham & Company LLC boosted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Wall Street’s consensus rating remains Moderate Buy, with an average price target of $26.44. Piper Sandler maintained an Overweight rating and raised its target to $25, while Needham increased its target to $35 and reiterated Buy. OrthoPediatrics analyst coverage
• Positive Sentiment: Several institutions increased their positions during the first half of the year. Millennium Management raised its stake by 55.3%, Goldman Sachs more than doubled its holdings, and institutional investors collectively own approximately 69.05% of outstanding shares.
• Positive Sentiment: OrthoPediatrics recently exceeded quarterly expectations, reporting revenue of $70.51 million versus the $68.21 million consensus estimate and a loss of $0.26 per share, better than the expected $0.30 loss. This suggests operating results are progressing ahead of forecasts, despite the company remaining unprofitable.
• Neutral Sentiment: The reported transactions appear in multiple director, major-shareholder and beneficial-ownership filings, so some disclosures may represent overlapping ownership records rather than separate sales. The reporting holders still controlled roughly 6.53 million shares after the transactions. SEC ownership filing
• Negative Sentiment: Director David Pelizzon and major shareholder Jennifer N. Pritzker reported sales totaling 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. The sales reduced reported ownership by 4.76% and may weigh on sentiment by creating an insider-selling overhang.
• Negative Sentiment: The same ownership group also reported sales of 10,131 shares on September 1 at $23.10, valued at about $234,000 per filing. While the 0.15% reduction is modest, the additional selling reinforces the near-term supply concern. OrthoPediatrics insider sale report

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.